About daphnecanada

This author has not yet filled in any details.
So far daphnecanada has created 24 blog entries.

Lanadelumab Added to NS Formulary

2021-09-13T15:48:46-06:00

Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova Scotia's drug formulary. To access this treatment,

Lanadelumab Added to NS Formulary2021-09-13T15:48:46-06:00

Congratulations Heather Dow

2021-07-07T15:06:47-06:00

Who is Heather Dow? Heather has been supporting HAE Canada in many ways over the years, from providing technical support for our virtual Patient Information Updates and organizing the AGM, to helping update our strategic

Congratulations Heather Dow2021-07-07T15:06:47-06:00

Winning the HAE Global Walk

2021-06-08T15:22:56-06:00

Congratulations to the Canadian HAE Community! Canadians logged the most steps to win the 2021 Global Walk for a third time. Thank you very much to all who participated - the efforts of all illustrate

Winning the HAE Global Walk2021-06-08T15:22:56-06:00

2021 HAE Day :-)

2021-05-16T11:34:41-06:00

Happy HAE Day and Happy 10th Anniversary! We hope everyone celebrated HAE Day :-) by doing something extra fun. Did you go for a hike? Did you plant some flowers? Make a special meal for

2021 HAE Day :-)2021-05-16T11:34:41-06:00

TAKHZYRO: Available in Saskatchewan

2021-05-11T08:55:08-06:00

HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab (TAKHZYRO), a subcutaneous preventative HAE treatment, to their provincial drug formulary. Please click here to read the Exceptional Drug Status

TAKHZYRO: Available in Saskatchewan2021-05-11T08:55:08-06:00

HAEGARDA: Available Across Canada

2021-05-03T12:52:12-06:00

We are over the moon that our members are telling us that they are excited about having access to HAEGARDA, a subcutaneous C1 esterase inhibitor (C1-INH) prophylaxis therapy for adolescent and adult HAE patients. We

HAEGARDA: Available Across Canada2021-05-03T12:52:12-06:00

TAKHZYRO now available in Newfoundland & Labrador

2021-05-03T15:14:46-06:00

We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was added to the Newfoundland & Labrador Prescription

TAKHZYRO now available in Newfoundland & Labrador2021-05-03T15:14:46-06:00

April 6 is the day for HAEGARDA in Canada!

2021-05-03T09:34:50-06:00

We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood Services (CBS) formulary. This means that all

April 6 is the day for HAEGARDA in Canada!2021-05-03T09:34:50-06:00

Takhzyro Added to the NIHB Formulary

2021-03-11T12:53:09-06:00

We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now access lanadelumab (TAKHZYRO) as a limited use

Takhzyro Added to the NIHB Formulary2021-03-11T12:53:09-06:00

Takhzyro soon available in Manitoba

2021-03-11T10:06:30-06:00

Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more, please make an appointment with your HAE

Takhzyro soon available in Manitoba2021-03-11T10:06:30-06:00
Go to Top